Press Releases for BVF

Press Releases
Wall St Sense Technical & Fundamental Reviews on Agrium Inc., Constellation Energy Group Inc., McAfee Inc., Biovail Corp., Total SA and Quanta Services Inc.
RidgewaterEquity.Com Free Fundamental Sector &Amp; Market Research on ALL, BVF, AXA, CBT, TUP and UA
Biovail to Present at Canaccord Adams Global Growth Conference
Biovail to Present at Canaccord Adams Global Growth Conference
Biovail Reports Second-Quarter 2009 Financial Results
Biovail Reports Second-Quarter 2009 Financial Results
Biovail Launches Share Repurchase Program
Biovail Launches Share Repurchase Program
Biovail Declares Quarterly Dividend
Biovail Declares Quarterly Dividend
Biovail Announces Second-Quarter 2009 Earnings Release, Conference-Call Details
Biovail Announces Second-Quarter 2009 Earnings Release, Conference-Call Details
InvestorSoup.com Issues Trading Outlook for Labopharm Inc.
Biovail Announces New Increased Revolving Credit Facility
Biovail Announces Pricing of Offering of US$300 Million Senior Convertible Notes Due 2014
Biovail Announces Offering of Senior Convertible Notes
Biovail to Participate at Upcoming Conferences
Biovail to Participate at Upcoming Conferences
Biovail Announces Results of 2009 Annual and Special Meeting of Shareholders
Biovail Announces Results of 2009 Annual and Special Meeting of Shareholders
Biovail Waives Deadline for Submitting Proxies
Biovail Waives Deadline for Submitting Proxies
Biovail Announces Settlement of Proxy Contest
Biovail Announces Settlement of Proxy Contest
Biovail Advises Shareholders to Vote Their Blue Proxy Today
Biovail Advises Shareholders to Vote Their Blue Proxy Today
Biovail Announces That RiskMetrics, Glass Lewis and PROXY Governance All Recommend Voting the BLUE Proxy “FOR” Biovail’s Director Nominees
Biovail Announces That RiskMetrics, Glass Lewis and PROXY Governance All Recommend Voting the BLUE Proxy “FOR” Biovail’s Director Nominees
Biovail Announces Acquisition of Worldwide Rights to Tetrabenazine
Biovail Announces Acquisition of Worldwide Rights to Tetrabenazine
Biovail Receives 2009 Corporate Award from National Organization for Rare Disorders
Biovail Receives 2009 Corporate Award from National Organization for Rare Disorders
Biovail Announces Termination of HSR Waiting Period, Closing of Acquisition of U.S. Rights to Wellbutrin XL®
Biovail Announces Termination of HSR Waiting Period, Closing of Acquisition of U.S. Rights to Wellbutrin XL®
Biovail Announces Termination of HSR Waiting Period, Closing of Acquisition of U.S. Rights to Wellbutrin XL®
Biovail Advises Shareholders to Use Their Blue Proxy to Reject Melnyk Nominees
Biovail Advises Shareholders to Use Their Blue Proxy to Reject Melnyk Nominees
Biovail to Participate at Upcoming Conferences
Biovail to Participate at Upcoming Conferences
Former Executive Director of the World Bank and CEO of OMERS Nominated as Directors for Biovail Corporation's Board of Directors
Former Executive Director of the World Bank and CEO of OMERS Nominated as Directors for Biovail Corporation's Board of Directors
Biovail Announces Dismissal of Securities Litigation
Biovail Announces Dismissal of Securities Litigation
ACADIA Pharmaceuticals and Biovail Announce Completion of Enrollment in First Pivotal Phase III Trial with Pimavanserin in Patients with Parkinson’s Disease Psychosis
ACADIA Pharmaceuticals and Biovail Announce Completion of Enrollment in First Pivotal Phase III Trial with Pimavanserin in Patients with Parkinson’s Disease Psychosis
Biovail Reports First-Quarter 2009 Financial Results
Biovail Declares Quarterly Dividend, Announces Change in Dividend Policy
GlaxoSmithKline to Divest US Rights for Wellbutrin XL(R) to Biovail for $510 Million
Biovail Announces Acquisition of U.S. Rights to Wellbutrin XL®
Biovail Announces U.S. Availability of Aplenzin™ Tablets
Biovail Announces U.S. Availability of Aplenzin™ Tablets
Biovail Appoints Rochelle Seide Ph.D., J.D. Vice-President, Intellectual Property
Biovail Appoints Rochelle Seide Ph.D., J.D. Vice-President, Intellectual Property
Biovail Announces Establishment of External Advisory Board
Biovail Announces Establishment of External Advisory Board
Biovail Announces Annual and Special Meeting of Shareholders
Biovail Announces Annual and Special Meeting of Shareholders
Biovail to Present at Barclays Capital Global Healthcare Conference
Biovail to Present at Barclays Capital Global Healthcare Conference
Biovail Declares Quarterly Dividend - Feb 26 2009 11:51PM
Biovail Reports Fourth Quarter, Year-End 2008 Financial Results
Biovail Reports Fourth Quarter, Year-End 2008 Financial Results
Biovail Declares Quarterly Dividend - Feb 26 2009 7:41AM
Biovail Declares Quarterly Dividend - Feb 26 2009 7:41AM
Biovail Receives Requisition from Dissident Shareholder Eugene Melnyk
Biovail Receives Requisition from Dissident Shareholder Eugene Melnyk
Biovail Announces Fourth-Quarter 2008 Earnings Release, Conference-Call Details
Biovail Announces Fourth-Quarter 2008 Earnings Release, Conference-Call Details
Biovail Announces Approval of Settlement Agreement with OSC
Biovail Announces Approval of Settlement Agreement with OSC
Biovail Reaches Settlement Agreement with OSC Staff
Biovail Reaches Settlement Agreement with OSC Staff
Biovail Announces Voluntary Recall of Certain Lots of Ultram® ER 100mg Tablets
Biovail Announces Voluntary Recall of Certain Lots of Ultram® ER 100mg Tablets
Biovail Announces Litigation Settlement
Biovail Announces Litigation Settlement
Biovail Enters into Commercial Alliance for Aplenzin™
Biovail Enters into Commercial Alliance for Aplenzin™
Biovail Announces Filing of ANDA for Quetiapine XR Tablets
Biovail Announces Filing of ANDA for Quetiapine XR Tablets
Biovail Announces U.S. Availability of Xenazine® Tablets
Biovail Announces U.S. Availability of Xenazine® Tablets
Biovail to Participate at Upcoming Conferences
Biovail to Participate at Upcoming Conferences
Biovail Reports Third-Quarter 2008 Financial Results
Biovail Reports Third-Quarter 2008 Financial Results
Biovail Declares Quarterly Dividend - Nov 6 2008 7:38AM
Biovail Declares Quarterly Dividend - Nov 6 2008 7:38AM
Biovail Appoints Dr. H. Christian Fibiger Senior Vice-President, Chief Scientific Officer
Biovail Appoints Dr. H. Christian Fibiger Senior Vice-President, Chief Scientific Officer
Biovail Announces Third-Quarter 2008 Earnings Release, Conference-Call Details
Biovail Announces Third-Quarter 2008 Earnings Release, Conference-Call Details
Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Biovail Corporation to Inquire About the Lead Plaintiff Position in Securities Fraud Class Action Lawsuit Before the December 8, 2008 Lead Plaintiff Deadline
INVESTOR ALERT: KGS Notifies Biovail Corporation Purchasers With Losses Greater Than $300,000, of Lead Plaintiff Application Deadline in Securities Class Action Lawsuit -- BVF
The Brualdi Law Firm, P.C. Announces Class Action Lawsuit Against Biovail Corporation
Izard Nobel LLP Announces Class Action Lawsuit against Biovail Corporation
Biovail Comments on Filing of Lawsuit
Biovail Comments on Filing of Lawsuit
Coughlin Stoia Geller Rudman & Robbins LLP Files Class Action Suit against Biovail Corporation
Biovail to Present at Natixis Bleichroeder Hidden Gems Conference